Best of the Week
Most Popular
1.US Paving the Way for Massive First Strike on North Korea Nuclear and Missile Infrastructure - Nadeem_Walayat
2.Trump Reset: US War With China, North Korea Nuclear Flashpoint - Video - Nadeem_Walayat
3.Silver Junior Mining Stocks 2017 Q2 Fundamentals - Zeal_LLC
4.Soaring Inflation Plunges UK Economy Into Stagflation, Triggers Government Pay Cap Panic! - Nadeem_Walayat
5.The Bitcoin Blueprint To Your Financial Freedom - Sean Keyes
6.North Korea 'Begging for War', 'Enough is Enough', is a US Nuclear Strike Imminent? - Nadeem_Walayat
7.Bitcoin Hits All-Time High and Smashes Through $5,000 As Gold Shows Continued Strength - Jeff_Berwick
8.2017 is NOT "Just Another Year" for the Stock Market: Here's Why - EWI
9.Gold : The Anatomy of the Bottoming Process - Rambus_Chartology
10.Bitcoin Falls 20% as Mobius and Chinese Regulators Warn - GoldCore
Last 7 days
Here’s Why Turkey Can’t Stay Out Of Syria - 25th Sep 17
Hidden Gems Shows A Foreboding Stock Market Future - 25th Sep 17
10 Reason You Should Use Ridesharing To Save Money - 25th Sep 17
Commodities King Gartman Says Gold Soon Reach $1,400 As Drums of War Grow Louder - 25th Sep 17
Stock Market Mixed Expectations, Will Stocks Continue Higher? - 25th Sep 17
22 charts and 52 questions that will make you Buy Gold - 25th Sep 17
Speculation Favors Overall Higher Silver Prices - 25th Sep 17
The Advertising Breakthrough Revolutionizing Gaming - 25th Sep 17
Stock Market Forming a Reluctant Top - 25th Sep 17
Grid Forex Strategy - All You Need to Know - 25th Sep 17
Catalonia, Kurdistan, Patriotism, Flags and Referendums - 24th Sep 17
Two Key Indicators Show the S&P 500 Becoming the New ‘Cash’ - 24th Sep 17
The Felling of Sheffield's Big Street Trees 2017 - Dobcroft Road - 24th Sep 17
Advantages of Forex Trading - 24th Sep 17
Stocks, Gold, Dollar, Bitcoin Markets Analysis - 23rd Sep 17
How Will We Be Affected by a Series of Rate Hikes? - 23rd Sep 17
Fed Quantitative Tightening Impact on Stocks and Gold - 22nd Sep 17
Bitcoin & Blockchain: All Hype or Part of a Financial Revolution? - 22nd Sep 17
Pensions and Debt Time Bomb In UK: £1 Trillion Crisis Looms - 22nd Sep 17
Will North Korea Boost Gold Prices? Part I - 22nd Sep 17
USDJPY Leads the way for a Resurgent Greenback - 22nd Sep 17
Day Trading Guide for Dummies - 22nd Sep 17
Short-Term Uncertainty, As Stocks Fluctuate Along Record Highs - 21st Sep 17
4 Reasons Gold is Starting to Look Attractive as Cryptocurrencies Falter - 21st Sep 17
Should Liners Invest in Shipping Software Solutions and Benefits of Using Packaged Shipping Software - 21st Sep 17
The 5 Biggest Bubbles In Markets Today - 20th Sep 17
Infographic: The Everything Bubble Is Ready to Pop - 20th Sep 17
Americans Don’t Grasp The Magnitude Of The Looming Pension Tsunami That May Hit Us Within 10 Years - 20th Sep 17
Stock Market Waiting Game... - 20th Sep 17
Precious Metals Sector is on Major Buy Signal - 20th Sep 17
US Equities Destined For Negative Returns In The Next 7 Years - 3 Assets To Invest In Instead - 20th Sep 17
Looking For the Next Big Stock? Look at Design - 20th Sep 17
Self Employed? Understanding Business Insurance - 19th Sep 17
Stock Market Bubble Fortunes - 19th Sep 17
USD/CHF – Verification of Breakout or Further Declines? - 19th Sep 17
Blockchain Tech: Don't Say You Didn't Know - 19th Sep 17
The Fed’s 2% Inflation Target Is Pointless - 19th Sep 17
How To Resolve the Korean Conundrum  - 19th Sep 17
A World Doomed to a Never Ending War - 19th Sep 17
What is Backtesting? And Why You Need Backtesting System? - 19th Sep 17

Market Oracle FREE Newsletter

3 Videos + 8 Charts = Opportunities You Need to See - Free

Trump’s FDA Chief May Implement Progressive Approval for Drugs

Companies / Healthcare Sector Dec 20, 2016 - 07:35 AM GMT

By: John_Mauldin

Companies

BY PATRICK COX : President-elect Trump's cabinet appointments are generating a great deal of attention and controversy. After eight years of Democrat rule, it would be foolish to expect otherwise.

One appointment, though, will have a profound impact on your health… and the health of your loved ones.


The “progressive approval” process for drugs

The first potential FDA chief appointee leaked by the Trump transition team is Jim O’Neill. Managing director of Peter Thiel’s Mithril Capital, O’Neill has publicly supported proposals to do away with the FDA’s requirement for phase 2 and 3 trials. Instead, he favors “progressive approval” of drugs and other medical technologies.

O’Neill would not be the first FDA head to favor progressive drug approval. Andrew von Eschenbach developed this system when he served as FDA chief. But during his tenure, Eschenbach was not able to put such a far-reaching reform into practice in the US.

The Japanese, though, saw the value of Eschenbach’s plan. They now use it for regenerative medicine. Japan legalizes therapies following proof of safety. Once a drug is in use, companies can move to phase 4. This means they monitor their patients and disclose efficacy data regularly.

If O’Neill gets the nod, he could implement progressive approval for drugs. But he would face fierce opposition from those who profit from the current system.

The current drug approval system is flawed

Big pharma benefits a great deal from the status quo. Since many small biotechs can’t fund most phase 2 or 3 trials, they give up significant ownership of their biotechnologies to these giants in exchange for financial help.

Many other organizations are also paid billions each year for services related to phase 2 and 3 clinical trials. They too will argue that doing away with those trials would endanger patients.

Since therapies would have to be proven safe before reaching the public, they will charge that patients will be at risk from using treatments that don’t work.

This, of course, is true. But it’s also true that patients are put at risk because they are denied access to unapproved but effective drugs.

Also, we pay much more for available drugs because companies must recoup costs imposed by the regulatory system. How big are those costs? Estimates of the average cost of one new medicine range from $1 to $4 billion.

Another side effect of the current system is that many drugs never leave the lab. These are drugs that could effectively treat serious illness but aren’t worth the cost of approval. This is because the patient population is too small to recoup approval costs.

The FDA has made efforts to help to help biotechs develop orphan drugs, but these steps have not been enough to make much of an impact.

Genomics and the need for a new regulatory process

Genomics has changed the way we treat illness. As the cost of genome sequencing falls, the ability to design drugs that work in small populations with specific genetic characteristics is rapidly increasing.

Eric Topol is the Director of the Scripps Translational Science Institute. He suggests that randomized clinical trials for this kind of indication are not just impractical, they’re unethical. InSilico Medicine’s Alex Zhavoronkov is one of the leading researchers in genomics-based personalized medicine. He believes we will be able to design and manufacture drugs for a single genome.

But how do you do a blinded controlled trial for a drug that may work on just one person?

This is not just an issue for the future. Many life-saving breakthroughs that could save millions of lives and reduce medical costs are stalled right now. Two of the most important areas of research are geroprotectors and induced tissue regeneration (ITR).

Geroprotectors are compounds that repair the systems that accelerate aging and age-related disease. Major universities and research organizations have found at least half a dozen molecules that could slow aging and extend health spans… even in older people.

Why haven’t you seen these compounds? Because phase 2 and 3 trials would take a decade or more… while increasing their prices by orders of magnitude.

Induced Tissue Regeneration (ITR) has even greater potential. ITR is an emerging technology that could reactivate the embryonic healing powers hidden deep in your DNA. It could restore lost limbs, broken spinal cords, or any other body part to youthful function. Eyes, hearts, joints, skin, and livers could be taken back in time using relatively simple compounds.

If it weren’t for the fact that Dr. Michael West is spearheading this new field, I would dismiss it as a pipe dream. West’s spinal cord stem cell therapy recently saved complete quadriplegics from a life of total dependency. Almost no one thought that he could do this. In fact, I got emails saying that the trial would fail, and this was after the first patient got back to ability to lift weights, text, and care for himself.

The important thing to note about this therapy is how long it took to get approved. West invented it over 20 years ago. It took that long to drag this miraculous biotechnology through the regulatory maze.

The big picture for ITR

Over the past 20 years, the pace of West's research and scientific progress has accelerated along with breakthroughs in computers and genomics. Now, he is on the verge of activating in adults the same genetic power evident in developing embryos. 

For years, I’ve gleaned what I could about this project by following West’s public statements and patent applications. Finally, he’s begun to tell the whole revolutionary story. Following the success of spinal cord technology, he laid out the big ITR picture in a keynote address to the prestigious World Stem Cell Summit.

ITR may be the biggest breakthrough in the history of medicine. The ability to make old and damaged organs and tissues young again will change countless lives. For millions of older people, though, it will come too late unless the regulatory bureaucracy is transformed to accelerate life-saving therapies.

Maybe Jim O’Neill will be the person to make it happen.

In the interest of transparency, I should note that I own stock in Michael West’s company BioTime (*see disclosure below).

Stay in the Loop on Life-Extending Research with Patrick Cox's Tech Digest

This weekly newsletter by biotech expert Patrick Cox highlights research that is much more advanced than most people know, and the profit potential for investors is vast. Read about the latest breakthroughs—from new, non-invasive cancer treatments to age-reversing nutraceuticals and vaccines that kill any virus–as well as the innovative companies that work on them. Get Tech Digest free in your inbox every Monday.

(*Disclosure: The editors or principals of Mauldin Economics have a position in this security. They have no plans to sell their position at this time. There is an ethics policy in place that specifies subscribers must receive advance notice should the editors or principals intend to sell.)

John Mauldin Archive

© 2005-2017 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Catching a Falling Financial Knife